$AMGN Headlines Amgen ends trials of stomach-cancer

New Post Public Reply Private Reply Replies (0) Message Board

Dec 7, 2014 at 1:02 PM

$AMGN Headlines

Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt

Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:22 p.m. Dec. 5, 2014 - TheStreet.com
Bayer Files Hemophilia A Drug Marketing Application in EU - Analyst Blog 10:20 a.m. Dec. 5, 2014 - Zacks.com
Amgen Inc. (AMGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 5, 2014 - Zacks.com
Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning - Analyst Blog 6:45 p.m. Dec. 4, 2014 - Zacks.com
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog 6:30 p.m. Dec. 4, 2014 - Zacks.com
Hot Drugmakers Build More Labs, Grab Space In Boston 3:47 p.m. Dec. 4, 2014 - Investors Business Daily
Gilead Sciences: An Alpha Stock Through The Good And Bad Times 3:14 p.m. Dec. 4, 2014 - Seeking Alpha
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog 3:10 p.m. Dec. 4, 2014 - Zacks.com
Cancer’s Super-Survivors 1:46 p.m. Dec. 4, 2014 - The Wall Street Journal Interactive Edition
Insider Trading Alert - CVT, ARAY And AMGN Traded By Insiders 10:15 a.m. Dec. 4, 2014 - TheStreet.com
Regeneron at 52-Week High on Eylea Priority Review Status - Analyst Blog 9:15 a.m. Dec. 4, 2014 - Zacks.com
Oncolytics Files for Orphan Drug Designation for Reolysin - Analyst Blog 4:30 p.m. Dec. 3, 2014 - Zacks.com
Biogen Up on Encouraging Interim Data on Alzheimer's Drug - Analyst Blog 2:33 p.m. Dec. 3, 2014 - Zacks.com
Amgen Wins U.S. Approval for Immunotherapy Against Leukemia 1:31 p.m. Dec. 3, 2014 - TheStreet.com
FDA clears Amgen blood cancer immunotherapy 1:25 p.m. Dec. 3, 2014 - Seeking Alpha
Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU - Analyst Blog 6:05 p.m. Dec. 2, 2014 - Zacks.com
Amgen (AMGN) Reaches New Lifetime High Today 9:45 a.m. Dec. 2, 2014 - TheStreet.com
Meet 5 Top Drug Stocks That Are Bolting Past Market 7:02 a.m. Dec. 2, 2014 - Investors Business Daily
'Fast Money' Recap: Energy Companies Ebb and Flow With Oil Prices 5:00 a.m. Dec. 2, 2014 - TheStreet.com

Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 9:15 a.m. Nov. 24, 2014 - PR Newswire - PRF
Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Nov. 18, 2014 - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire
Amgen To Present At The Jefferies Global Healthcare Conference 4:15 p.m. Nov. 14, 2014 - PR Newswire - PRF
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver 9:31 a.m. Nov. 13, 2014 - PR Newswire - PRF
Biothera Names Carey Anderson VP of Regulatory Affairs 9:30 a.m. Nov. 13, 2014 - BusinessWire - BZX
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions 4:35 p.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab 4:01 p.m. Nov. 12, 2014 - PR Newswire - PRF
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide 9:00 a.m. Nov. 12, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Long March Reflections: Lesson of Adaptation Endures

Ever stood in a place where history feels so heavy you can almost touch it? That's Lazikou, a gorge in southern Gansu, where ninety years ago, young soldiers of China's Red Army faced a seemingly impassable barrier. Yet, they managed to climb, transform a military retreat into legend, and essentially shape the nation's path ahead. It's a feat that still sends ripples...

Firehawk Defense Secures $150M, Valuation Hits $1.4B

Firehawk Defense Lands Major Funding Think about it—Firehawk Defense, a gutsy Dallas-based new-kid-on-the-block, just snagged a whopping $150 million in fresh funding. The news? Their valuation's now sitting pretty at $1.4 billion. Not peanuts, by any means. For a company in the artillery game, that's a blast of an announcement. They're predicting they'll become the big...

Vertiv's Explosive Q3 Growth: A 2026 Power Move

Vertiv's Third Quarter Triumph Imagine a company blowing past expectations like a hot knife through butter—yeah, that's Vertiv for you in 2026. These guys didn’t just ride the wave; they created a tsunami in the digital infrastructure sector. Net sales ballooned by a staggering 61% compared to last year's same quarter, pulling in $4.313 billion. When you consider the...

Amgen Q3 2026 Results: What Investors Should Know

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

2026 Data Integration Stars: User Sentiments Revealed

Users Crown Data Integration Champions Right out of the gate, let's make one thing clear: when you're picking a data integration solution, you're essentially hitching your wagon to a vendor. This partnership, like any, can make or break your operations, and no one knows this better than the folks who've been through the trenches. Enter Infotech's 2026 Emotional Footprint...

Right College Fit Crucial for Graduation Rates

Navigating College Choices: More Than Just a Hunch When it comes to picking the right college, a lot of folks think it's like shooting in the dark—it's more than just a blind dart throw at a life map. According to a new report from the College Board, aligning with the right academic institution isn't merely a nice-to-have deal; it fundamentally shifts the odds in favor...

GeoComm and Rypplzz Team Up for 3D Mapping Breakthrough

Cracking the Mystery of Multilevel Locations Let me tell you, when lives hang in the balance, every second counts. We've all seen the chaos when first responders are trying to pinpoint someone's location inside a building with more floors than a loaf of bread. Enter GeoComm and Rypplzz, the new superheroes in this story. These two companies have realized the opportunity...

Probiotics in Animal Feed: Market Reaches $8.76B by 2031

Let's cut straight to the chase: the probiotics in animal feed market is steaming ahead, set to grow from a respectable $5.82 billion in 2026 to a hearty $8.76 billion by 2031. We're talking about a solid CAGR of 8.5% here. Now that's the kind of growth trajectory that gets even the most jaded traders sitting up and taking notice. Big Numbers in Livestock Nutrition...

JELD-WEN Kicks Off 2027 Senior Notes Exchange

A Fresh Play: Swapping Old for New With a fresh brew in hand and the latest company maneuvers on the table, JELD-WEN's move to exchange its 4.875% Senior Notes due 2027 for new secured notes maturing in 2031 comes into focus. This ain't just some routine shuffling of papers. They're calling up eligible folks holding onto those old notes, saying, 'Why stick with the old...